High-
risk health workers
First
responders
All-
ages at high risk
Older
adults congregate/overcrowded
K-
12 teachers, staff, childcare workers
Critical
workers in high-risk settings
Moderate
comorbid conditions
Homeless
shelters
Incarcerated
people and staff
All
older adults
Younger
adults
Children
Workers
in important industries
Everyone
else
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% of total population by priority group
5%
1%
6%
5%
3%
1%
12%
0%
1%
4%
14%
25%
8%
15%
% of population with vaccine-induced immunity by deal under scenario B assumptions:
Moderna
3%
0%
4%
3%
2%
1%
8%
0%
1%
3%
9%
3%
0%
0%
BioNTech/Pfizer
3%
0%
4%
3%
2%
1%
8%
0%
1%
3%
9%
9%
0%
0%
Johnson & Johnson (Janssen)
3%
0%
4%
3%
2%
1%
8%
0%
1%
3%
9%
16%
5%
10%
Oxford/AstraZeneca
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Novavax
3%
0%
4%
1%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Sanofi/GSK
3%
0%
4%
3%
2%
1%
8%
0%
1%
3%
9%
15%
0%
0%
Valneva
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Total across all deals
3%
0%
4%
3%
2%
1%
8%
0%
1%
3%
9%
16%
5%
10%